Theratechnologies Inc T.TH

ADC Plus immunotherapy a proven concept

[scarlet1967]

The recent preclinical results showed TH1902 in combination with an immunotherapy drug (check point inhibitors blocking PD-L1)) significantly improved the survival rate in melanoma which is one of the cancers with high sort1 expression.
It seems those check point inhibitors block the interaction of some proteins (PD-L1/PD-1) responsible for stopping the immune system attacking the cancer cells. So basically cancer cells can’t hide from body’s immune defense.
Now the antibody conjugate PADCEV in combination with immunotherapy agent KEYTRUDA which also prevents the interaction between PD-1 and PD-L1 have been approved for first-line treatment of advanced or metastatic urothelial cancer and they are also conducting trials with the same drugs for untreated advanced urothelial cancer.
“The ongoing phase 3 EV-302 trial (NCT04223856, also known as KEYNOTE-A39) evaluating the clinical benefit of PADCEV in combination with pembrolizumab in patients with previously untreated advanced urothelial cancer is intended to serve as the pivotal confirmatory trial for the U.S. accelerated approval. It is also intended to serve as the basis for global registrations. The trial has completed global enrollment, with the China extension of the study currently enrolling patients.”

Point is a combination therapy between two different anti-cancer agents with two different MOAs seems to be a clinically valid approach to fight cancer. I believe the combo therapy boost the partnership odds for TH1902 which explains the reason why they conducted those preclinical trials.

FDA Grants Accelerated Approval for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (prnewswire.com)

[Trogarzon]

That will be presented April 18 at the AACR.  I have high hopes for this. 

[Wino115]

If those AACR poster results are very strong, it shoudl get some attention. I completely agree that there are 3 possibilities for them to push their science in combos and as a pre/post anti=metastatic. It would be a real wildcard if those numbers are good and they can convince someone to come in on a small trial. Cost wouldn't be high for that versus other types of trials. Given the market

[palinc2000]

Have you noticed how Richard Beliveau is noticeably absent from all presentations.I cant say that I miss him as I found him to be too exhuberant in past presentations and he seems loke a person who likes to be in the limelight..I think (but not sure) that Beliveau  was instrumental in convincing THTX into purchasing Katana .......